• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, December 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

HIV: an innovative therapeutic breakthrough to optimize the immune system

Bioengineer by Bioengineer
February 8, 2021
in Biology
Reading Time: 3 mins read
1
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A therapeutic approach to restore the effectiveness of immune cells

IMAGE

Credit: INRS

Prompted by the need to improve conventional treatments for people infected with the human immunodeficiency virus (HIV-1), a team from the Institut national de la recherche scientifique (INRS) has identified a therapeutic approach to restore the effectiveness of immune cells. The study, led by doctoral student Hamza Loucif and Professor Julien van Grevenynghe, was published in the journal Autophagy.

Most people infected with HIV-1 require daily antiretroviral therapy to control the infection. These drugs cause significant side effects without fully restoring the normal functioning of the immune system. Yet, a specific group of patients, called “elite controllers”, are able to live with the infection without any drug intervention.

“They represent an incredible model for detecting, at the molecular level, what needs to be improved for other patients,” says Professor Julien van Grevenynghe. “That’s why the team of immunologists wanted to find out what differentiates them from conventionally treated patients to develop new weapons against infection.”

Scientists demonstrated that the strength of elite controllers comes from their energy metabolism within CD8 lymphocytes. “Cells require energy, produced in the mitochondria to protect the body and carry out their functions. However, this energy is not used effectively by treated patients. Due to a deregulation of the metabolism, the cells are weakened in their immune function,” explains Professor van Grevenynghe, who has worked on HIV for 15 years.

Re-educating cells

This energy deficiency is not permanent. Indeed, the research team demonstrated that CD8 lymphocytes can be “re-educated” using a soluble protein that optimizes their energy intake and immune function. “The protein, called interleukin-21 (IL-21), restores mitochondrial energy metabolism through a cell recycling process called autophagy. For elite controllers, the degradation of lipid reserves through autophagy, or lipophagy, is highly effective,” explains the Ph.D. student.

“These results have an undeniable therapeutic interest, as the protein already exists! Moreover, the mere fact that elite controllers exist is proof in itself that we will one day be able to survive the infection without aggressive treatment,” Professor van Grevenynghe enthusiastically points out. “We might ultimately be thinking about ending the treatment. The cells could also respond better to vaccination and treatment with better energy efficiency.”

All the immune protection associated with CD8 lymphocytes comes from the presence of CD4 lymphocytes. These cells act as orchestra conductors’ cells of the immune system. Therefore, the research team wants to determine if CD4 lymphocytes also have a metabolic advantage. Ultimately, the group wants to test their therapeutic approach in humanized mouse models and even macaques.

An additional benefit of this breakthrough is that the results of the study would not be limited to HIV-1 alone. “A comparison can be made with other pathologies associated with persistent inflammation, such as cancer, diabetes and even COVID-19 with lung inflammation,” notes Julien van Grevenynghe.

###

About the study

The article “Lipophagy confers a key metabolic advantage that ensures protective CD8A T-cell responses against HIV-1”, by Hamza Loucif, Xavier Dagenais-Lussier, Cherifa Beji, Léna Cassin, Hani Jrade, Roman Tellitchenko, Jean-Pierre Routy, David Olagnier, and Julien van Grevenynghe, was published on January 18, 2021 in the journal Autophagy. The study was financially supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Fonds de recherche du Québec – Santé.

About INRS

INRS is a university dedicated exclusively to graduate level research and training. Since its creation in 1969, INRS has played an active role in Quebec’s economic, social, and cultural development and is ranked first for research intensity in Quebec and in Canada. INRS is made up of four interdisciplinary research and training centres in Quebec City, Montreal, Laval, and Varennes, with expertise in strategic sectors: Eau Terre Environnement, Énergie Matériaux Télécommunications, Urbanisation Culture Société, and Armand-Frappier Santé Biotechnologie. The INRS community includes more than 1,400 students, postdoctoral fellows, faculty members, and staff.

Source :

Audrey-Maude Vézina

Service des communications de l’INRS

418 254-2156

[email protected]

Media Contact
Audrey-Maude Vézina
[email protected]

Related Journal Article

http://dx.doi.org/10.1080/15548627.2021.1874134

Tags: AIDS/HIVBiologyImmunology/Allergies/AsthmaInfectious/Emerging DiseasesMedicine/HealthMetabolism/Metabolic DiseasesMicrobiologyMolecular BiologyPublic HealthVirology
Share15Tweet9Share3ShareShareShare2

Related Posts

BCL2 Gene Linked to Canine Mammary Tumors Enhanced

BCL2 Gene Linked to Canine Mammary Tumors Enhanced

December 20, 2025
Unveiling Genomes: Vincetoxicum Pycnostelma Revealed

Unveiling Genomes: Vincetoxicum Pycnostelma Revealed

December 20, 2025

Targeted Knock-In of Mouse Y Chromosomal Genes

December 20, 2025

Choosing Models: Linking Cat Intake to Socioeconomics

December 19, 2025
Please login to join discussion

POPULAR NEWS

  • Nurses’ Views on Online Learning: Effects on Performance

    Nurses’ Views on Online Learning: Effects on Performance

    70 shares
    Share 28 Tweet 18
  • NSF funds machine-learning research at UNO and UNL to study energy requirements of walking in older adults

    71 shares
    Share 28 Tweet 18
  • Unraveling Levofloxacin’s Impact on Brain Function

    53 shares
    Share 21 Tweet 13
  • Exploring Audiology Accessibility in Johannesburg, South Africa

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Trial Tests Sensorimotor Stimulation for High-Risk Newborns

Why Multiregional Accounting Matters for Corporate Emissions

Predicting Hospitalization Disability in Older Heart Failure Patients

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 70 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.